The Beta Nerve Growth Factor pipeline drugs market research report outlays comprehensive information on the Beta Nerve Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Beta Nerve Growth Factor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System, Dermatology, Cardiovascular, and Musculoskeletal Disorders which include the indications Cancer Pain, Pain, Diabetic Foot Ulcers, Pressure Ulcers, Myocardial Infarction, Cardiac Arrest, and Osteoarthritis. It also reviews key players involved in Beta Nerve Growth Factor targeted therapeutics development with respective active and dormant or discontinued products.
The Beta Nerve Growth Factor pipeline targets constitutes close to 14 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 6, 2, 1, 3, and 2 respectively.
Beta Nerve Growth Factor overview
Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI.
For a complete picture of Beta Nerve Growth Factor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.